Strategic Overview of Patenting Activity in Pharma Sector of BRIC Countries

Strategic Overview of Patenting Activity in Pharma Sector of BRIC Countries

Patenting Trends, IP Policy Developments, and Strategic Insights

RELEASE DATE
20-Sep-2015
REGION
North America
Research Code: D69A-01-00-00-00
SKU: LS00085-NA-MR_16926
$4,950.00
In stock
SKU
LS00085-NA-MR_16926
$4,950.00
Links

Pay by invoice

ENQUIRE NOW

Description

As developed markets are starting to witness slower growth rate; emerging markets, witnessing higher growth rate, are becoming key driver of revenue growth for multinational pharma companies. Much of this growth in Pharma sector of emerging markets is likely to be driven by BRIC, Mexico, and Turkey. This research service aims to highlight opportunities and risks in pharma sector of BRIC countries from a patenting perspective. This report also provides an overview of recent IP policy related developments and its business impact.

Table of Contents

Active Patent Stock of “Big Pharma” Companies in BRIC Countries

Patenting TrendsPharmaceuticals Sector–India

Patenting Activity at Indian Patent Office (IPO) in Pharma Sector

Patenting Activity by Indian Inventors GloballyInventor Geographical Location: IndiaPatent Offices Coverage: Global

IP Policy Update: Recent Case Studies

Case Study 1: Novartis vs. Cancer Patients Aid Association (CPAA)

Case Study 2: Bayer vs. Natco

Patenting TrendsPharmaceuticals Sector–China

Patenting Activity at Chinese Patent Office (SIPO) in Pharma Sector

Patenting activity by Chinese Inventors GloballyInventor Geographical Location: ChinaPatent Offices Coverage: Global

Patenting TrendsPharmaceuticals Sector–Brazil

Patenting Activity in Pharma Sector at Brazilian Patent Office (INPI)

Patenting Activity by Brazilian Inventors GloballyInventor Geographical Location: BrazilPatent Offices Coverage: Global

Patenting TrendsPharmaceuticals Sector–Russia

Patenting Activity in Pharma Sector at Russian Patent Office

Appendix

The Frost & Sullivan Story

Value Proposition: Future of Your Company & Career

Global Perspective

Industry Convergence

360º Research Perspective

Implementation Excellence

Our Blue Ocean Strategy

Related Research

2016-17 Outlook for Indian Agriculture and Rural Demand

Release Date: 18-May-16
Region: Global

Monthly CPI & WPI Inflation, April 2016

Release Date: 18-May-16
Region: Global

India Investment Tracker January–March 2016

Release Date: 18-May-16
Region: South Asia, Middle East & North Africa

Country Profile – Russia

Release Date: 13-May-16
Region: Asia Pacific

North American Protein Ingredients Market, Forecast to 2020

Release Date: 13-May-16
Region: North America

Global Economic Tracker—Insights and Trends (GET-IT)—Emerging Middle East and Africa Q2 2016

Release Date: 12-May-16
Region: South Asia, Middle East & North Africa

Middle East and North Africa Investment Tracker January-March 2016

Release Date: 11-May-16
Region: South Asia, Middle East & North Africa

Asia-Pacific Telehealth Market Outlook, Forecast to 2020

Release Date: 11-May-16
Region: Asia Pacific

Digital Transformation in the Global Food & Agriculture Market

Release Date: 9-May-2016
Region: North America
Since the introduction of Lucentis in 2006, vascular endothelial growth factor (VEGF) antagonists have become the clear choice in treatment for age related macular degeneration, diabetic macular edema, and retinal vein occlusion due to their high efficacy and safety. This research service evaluates the US market for the pharmaceutical management of AMD, DME, and RVO from 2009 to 2017, with 2012 as the base year. Segmentation by disorder is provided. Included are products on the market, products in development, and patient and revenue forecasts. Market challenges, drivers, and restraints are identified and assessed.
More Information
No Index No
Podcast No
Author Manmohan Singh
WIP Number D69A-01-00-00-00
Is Prebook No